In embolisation-eligible hepatocellular carcinoma, durvalumab plus tremelimumab plus lenvatinib with TACE improved median PFS vs TACE alone (13·0 vs 9·8 months; HR 0·70); overall survival did not differ significantly (HR 0·84; p=0·18).
RCTn = 760
Kudo et al. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study